VEXAS is a recently identified rare genetic disorder associated with somatic mutations in the UBA1 gene. Given the variability in disease presentation & the limited number of studies to date, an international multidisciplinary panel of VEXAS experts was convened to provide guidance to healthcare providers on the condition’s management. We spoke to experts on the panel about the resulting guidance document.
A rheumatologist & lupus expert reviews lupus nephritis treatment, questioning proteinuria cutoffs & ACR guidelines, advocating for newer therapies & end-of-treatment biopsies.
Review 28 recommendations covering proteinuria screening, biopsy indications & triple therapy regimens for lupus nephritis.
At a session of ACR Convergence 2024, speakers shared key elements of the new guideline on the screening, treatment and overall management of lupus nephritis in children and adults.1 This guideline attempts to balance the risks of medication side effects with the important goal of preserving kidney function. This is the ACR’s first lupus guideline…
At this ACR Convergence session, experts provided an overview of the new ACR guideline for juvenile idiopathic arthritis.
Updating the last iteration in 1999, the new ACR Guideline for Management of SLE was unveiled at ACR Convergence 2025, providing rheumatologists an organ-based approach for therapeutic options for specific lupus manifestations.
New EULAR/ACR criteria help stratify RA risk in patients with arthralgia. Learn how these criteria guide earlier interventions & improve trial rigor.
New global criteria for pediatric CNO aim to boost research & improve care for this rare autoinflammatory bone disease.
Pediatric rheumatologic diseases are characterized by high rates of anxiety & depression known to impact health-related outcomes. CARRA and the ACR developed guidance statements to assess & manage mental health concerns for youths in pediatric rheumatology practice.
Over 50% of patients with systemic sclerosis (SSc) develop interstitial lung disease (ILD), and rheumatologists have long recognized this major cause of morbidity and mortality.1 Sindhu R. Johnson, MD, PhD, professor of medicine at the University of Toronto, Canada, and director of the Toronto Scleroderma Program, notes that more recent studies have increased our awareness…